Author: Matthew Nelson|| Date Published: August 7, 2020
An SRI International division has secured a potential seven-year, $100M contract to help a National Institutes of Health component develop methods to medical conditions caused by direct exposure or contamination from radioactive materials.
SRI Biosciences will support the National Institute of Allergy and Infectious Diseases in research and development of medical countermeasures for radiological and nuclear emergencies, the nonprofit said Wednesday.
The partnership will also explore biological dosimetry tests and advance candidate treatments for acute radiation syndromes, delayed effects from acute radiation exposure and internal radionuclide contamination.
Both NIH and NIAID have worked with SRI Biosciences to develop radiation therapies as part of a contract slated to expire this month.
PDW is acquiring Vanteon to expand tactical communications capabilities The acquisition will bring expertise in RF systems, software-defined radios and…
CISA is planning a $100 million cyber operations contract supporting threat-hunting missions The requirement will provide technical and operational support…
Valiant Solutions is expanding its cybersecurity portfolio through the acquisition of BreakPoint Labs The acquisition will bring operational technology security,…
